Merz Pharma Group has announced that it will commence its tender off for all BioForm Medial, Inc. (NASDAQ:BFRM) outstanding shares for $5.45 per share. The offer was made by the company’s wholly owned subsidiary Vine Acquisition corp. The offer is scheduled to expire on February 12, 2010 at midnight. Vine Acquisition will merge with and into BioForm Medical, pursuant to the terms and conditions of the agreement. For more information, contact MacKenzie Partners’ Amy Bilbija, at 1.650.798.5206.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Skin does more than hold your insides in, and Merz Pharmaceuticals is there to help. Merz Pharmaceuticals, the US subsidiary of German drugmaker Merz, develops and distributes prescription and over-the-counter pharmaceutical treatments for skin and nail care. The company's products include Mederma, which is used to reduce the appearance of scarring; Appearex, which treats weak and brittle nails; and Naftin, a topical antifungal. Merz also sells the Aqua Glycolic line of skin cleansers and moisturizers. The company distributes a handful of non-dermatology products developed by its parent company, and is conducting research into aesthetic dermatology products.
Skin does more than hold your insides in, and Merz Pharmaceuticals is there to help. Merz Pharmaceuticals, the US subsidiary of German drugmaker Merz, develops and distributes prescription and over-the-counter pharmaceutical treatments for skin and nail care. The company's products include Mederma, which is used to reduce the appearance of scarring; Appearex, which treats weak and brittle nails; and Naftin, a topical antifungal. Merz also sells the Aqua Glycolic line of skin cleansers and moisturizers. The company distributes a handful of non-dermatology products developed by its parent company, and is conducting research into aesthetic dermatology products.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
